BD MiniDraw™ Capillary Blood Collection System Enables Lab-Quality Blood Testing from Less Invasive Method than Venous Collection in More Convenient Locations
FRANKLIN LAKES, N.J., Dec. 7, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.
The BD MiniDraw™ Capillary Blood Collection System is less invasive than a traditional venous blood draw by using capillary blood collected from a patient's finger by a trained healthcare worker, without the need for a phlebotomist to collect blood from a vein. The innovative design provides a sample that produces lab-quality blood test results from a fraction of the volume of traditional venous collections. It is less invasive than traditional venous blood collection methods and more convenient for the patient by expanding access to blood collection to new locations, including retail pharmacies. The device may provide a better patient experience and has the potential to transform diagnostic testing.
The 510(k) clearances include low-volume blood collection for a lipid panel, selected chemistry tests, and hemoglobin and hematocrit (H&H) testing. These tests are among the most commonly ordered lab tests and can be used to diagnose and monitor a variety of chronic conditions from hypertension to high cholesterol. BD plans to expand blood tests enabled by BD MiniDraw™ Collection System in the future.
"Because the BD MiniDraw™ Collection System enables blood collection at non-traditional sites that may be more convenient—like your local pharmacy rather than a standalone lab—we can expand health equity and access, and make it easier for patients to get the blood tests they need both for preventative care and the management of chronic conditions," said Dave Hickey, executive vice president and president of Life Sciences for BD. "This innovation is our strategy and pipeline coming to life, and proof of our commitment to enabling diagnostics and care in alternate settings."
Traditionally when a patient requires "blood work," a doctor orders the test, and an appointment is made at a laboratory service center where a nurse or phlebotomist draws tubes of blood from the patient's vein. The BD MiniDraw™ Collection System has the potential to transform this experience by expanding blood testing to new, more convenient settings, which can benefit patients, health care providers and collection sites.
"BD has a 125-year history of transforming health care and expanding access to critical health innovations and technologies," said Bridget Bagnato, worldwide president of Specimen Management for BD. "Consumers want more convenience, a better experience and to take more control over their health. We believe the BD MiniDraw™ Collection System is potentially a game-changing innovation that combines convenience and better patient experience with lab-quality results."
For patients, capillary collection with the BD MiniDraw™ Collection System provides the convenience of having blood drawn somewhere they already frequent, like a retail pharmacy or grocery store, which may have longer hours of operation and be closer to where they live or work. For these non-traditional collection sites, it enables expansion beyond existing health and wellness programs like administering vaccinations and can generate additional store traffic.
For health care providers, capillary blood collection could be offered at a physician's office without the need for a phlebotomist. Making blood collection easier and less invasive may improve patient adherence to blood testing, for example, as part of annual wellness checks, which could lead to earlier diagnosis and better monitoring of chronic conditions.
In May 2022, BD and Babson Diagnostics announced an expansion of their original strategic partnership agreement, announced in 2020, to advance development of the Babson BetterWay™ blood testing ecosystem, which includes the BD MiniDraw™ Collection System and Babson's proprietary automated sample-handling and analytical technologies. These were designed to work together to enable blood testing that requires only a fraction of the sample volume of traditional venipuncture methods without sacrificing quality or accuracy.
BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
VP, Public Relations
Sr. Director, Investor Relations
SOURCE BD (Becton, Dickinson and Company)